BioCentury
ARTICLE | Company News

Repligen, Pfizer deal

January 7, 2013 8:00 AM UTC

Repligen granted Pfizer exclusive, worldwide rights to develop and commercialize Repligen's spinal muscular atrophy (SMA) program, which includes lead candidate RG3039 and undisclosed backup SMA compounds. Repligen will receive $5 million up front and is eligible for up to $65 million in development and commercialization milestones, plus tiered royalties on any potential SMA compounds developed under the deal. Repligen is responsible for completing the first two cohorts of an ongoing Phase I trial of RG3039 in healthy volunteers, which is expected this quarter, after which Pfizer will assume responsibility for the small molecule inhibitor of decapping enzyme scavenger (DCPS). Repligen licensed rights to RG3039 in 2009 from the not-for-profit Families of Spinal Muscular Atrophy, which funded and conducted preclinical development of the product. ...